Neovasc Inc. (NVC) Announces Publication of Tiara Acute Preclinical Data in Journal of American College of Cardiology
9/18/2012 9:45:41 AM
VANCOUVER, Sept. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today
announced that acute results from preclinical studies of its TiaraTM valve for the transcatheter treatment of mitral regurgitation were
published in the Journal of the American College of Cardiology (JACC). The study reports that the initial experience with the Tiara
transcatheter mitral valve was encouraging and that implantation of
Tiara valves was feasible, relatively straightforward and resulted in a
securely-implanted, well-functioning device that maintained good
hemodynamics in the test animals. The study, which will be published
in the October 9, 2012 edition of JACC, is currently available on-line.
"We are very pleased with the results of our Tiara implantations in
preclinical animal models," noted Alexei Marko, CEO of Neovasc.
"Publication of the first results from the acute phase of these studies
in a prestigious journal such as JACC highlights the potential value of
Tiara for the treatment of patients with mitral regurgitation who
cannot be treated surgically. We look forward to sharing long-term
Tiara results from studies in chronic animal models at TCT 2012 next
month."
In the published study, Tiara valves were implanted successfully in 81%
of the test animals, with total procedure times ranging from 17 to 26
minutes. In the successful implantations, angiographic and echo
imaging demonstrated excellent function of the Tiara, with no
obstruction of the left ventricular outflow tract, no pericardial
effusion, no encroachment on the aortic valve, no transvalvular
gradients and most importantly, no significant paravalvular leak. All
animals remained hemodynamically stable during the implant procedure
without the need for rapid pacing.
The report, Tiara: A Novel Catheter-Based Mitral Valve Bioprosthesis: Initial
Experiments and Short-Term Pre-Clinical Results, was authored by Shmuel Banai, MD, E. Marc Jolicoeur, MD, Marc Schwartz,
RCIS, Patrick Garceau, MD, Simon Biner, MD, Jean-Francois Tanguay, MD,
Raymond Cartier, MD, Stefan Verheye, MD, Christopher J. White, MD and
Elazer Edelman, MD, PhD. It is being published in the Journal of the American College of Cardiology, Vol. 60, # 15, 2012, and is currently available on-line at: http://content.onlinejacc.org/article.aspx?articleid=1358177.
About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc Reducer
for the treatment of refractory angina, the Tiara technology in
development for the transcatheter treatment of mitral valve disease and
a line of advanced biological tissue products that are used as key
components in a variety of third-party medical products, such as
vascular surgical patches and transcatheter heart valves. For more
information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects,"
and "will" and words of similar import, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward looking statements involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions, both
nationally and in the regions in which the Company operates; history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product
candidates, ability to properly integrate newly acquired businesses,
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and other
claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking
statements are reasonable based on the information available to it on
the date such statements were made, no assurances can be given as to
the future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as otherwise
required by applicable law.
SOURCE Neovasc Inc.
|